4D Molecular Therapeutics (FDMT) Announces Key Company Update and 2026 Development Milestones
EMERYVILLE, Calif., January 7, 2026 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a leading late-stage biotechnology company focused on disease-targeted therapeutics, today provided a significant corporate update and outlined anticipated milestones for its primary product candidate, 4D-150, in the severe retinal vascular disease landscape.
Enrollment Progress in 4D-150 Phase 3 Trials for Retinal Diseases
4D Molecular Therapeutics is witnessing robust enrollment in its Phase 3 clinical trials for 4D-150, designed to address Wet Age-related Macular Degeneration (AMD). The company's 4FRONT-1 trial, which is pivotal for regulatory approval, is on schedule to complete enrollment by the end of the first quarter of 2026. As of January 6, 2026, a total of 381 patients have either been randomized or approved for randomization.
In 2026, 4DMT anticipates several key milestones:
- 4FRONT Global Phase 3 Program: Target enrollment increased from 400 to 480 patients per trial.
- The program aims for approximately 90% power with a noninferiority margin of 4 letters.
- 4FRONT-1 North American Trial: Completion of enrollment is on track for Q1 2026, with topline data expected in H1 2027.
- 4FRONT-2 Global Trial: Enrollment targeting completion by H2 2026 with topline results anticipated in H2 2027.
- PRISM Phase 1/2 Trial: Presentation of 2-year Phase 2b data expected in mid-2026.
- 4D-150 for Diabetic Macular Edema: Phase 3 trial design to be released in mid-2026, with global trial initiation expected in H2 2026.
Leadership Changes at 4DMT to Enhance Clinical Operations
To support late-stage execution and commercial readiness, 4D Molecular Therapeutics has appointed Glenn P. Sblendorio to its Board of Directors. Mr. Sblendorio brings extensive experience from his tenure as President and CEO at IVERIC Bio during its acquisition by Astellas Pharma. His expertise will be crucial as the company transitions toward commercialization of 4D-150.
Additional leadership changes include:
- Katy Barglow, Ph.D.: Promoted to Chief Technical Officer, she will oversee the transition to commercial manufacturing.
- Kim Maplestone: Elevated to Chief Clinical Operations Officer, focusing on global clinical operations for regulatory submissions.
- Chris Simms: Expanding role to Chief Commercial & Business Officer to include business development oversight.
- Fred Kamal, Ph.D.: Transitioning to Chief Technical Advisor, supporting CMC and regulatory strategy for 4D-150.
- David Kirn, M.D.: Assuming dual roles as President and Chief Executive Officer.
Company Financial Highlights and Future Outlook
As of December 31, 2025, 4DMT reported a strong financial position with $514 million in cash, cash equivalents, and marketable securities. This funding is anticipated to support ongoing operations into the latter half of 2028, allowing for continued development of the 4D-150 pipeline.
Upcoming Presentation at the J.P. Morgan Healthcare Conference
4D Molecular Therapeutics will present its strategic outlook during the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 AM PT. Interested parties can access the presentation via the conference's webcast link, with an archived version available on the company's Investors section for up to a year.
About 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics (FDMT) is dedicated to developing therapeutics that target diseases with the potential to redefine treatment paradigms, particularly for patients with retinal diseases. The lead candidate, 4D-150, aims to significantly reduce treatment burdens through sustained release of anti-VEGF therapeutics via a single intravitreal injection. The company also has several promising candidates in various stages of clinical development, including for Cystic Fibrosis and A1AT Lung Disease.